Sunshine Biopharma Inc
SBFM
查看详细走势图
1.200USD
+0.050+4.35%
收盘 02/06, 16:00（美东）报价延迟15分钟
5.47M总市值
0.23市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.35%
5天
-1.64%
1月
-14.89%
6月
-14.29%
今年开始到现在
-2.44%
1年
-52.00%
查看详细走势图
TradingKey Sunshine Biopharma Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Sunshine Biopharma Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名110/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.00。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Sunshine Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Sunshine Biopharma Inc亮点
亮点风险
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
业绩高增长
公司营业收入稳步增长，连续3年增长702.52%
业绩增长期
公司处于发展阶段，最新年度总收入34.87M美元
估值高估
公司最新PE估值0.23，处于3年历史高位
机构减仓
最新机构持股370.31K股，环比减少26.68%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值55.70K
分析师目标
根据
1
位分析师
买入
评级
6.000
目标均价
+395.87%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Sunshine Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Sunshine Biopharma Inc简介
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
公司代码SBFM
公司Sunshine Biopharma Inc
CEOSlilaty (Steve N)
网址https://www.sunshinebiopharma.com/
相关品种
